Abstract: A crutch having a first side direction, a second side direction opposite the first side direction, a third side direction perpendicular to the first side direction and a fourth side direction opposite the third side direction, the crutch including an elongate leg having a top end, a top portion, a middle portion, a bottom portion, and a bottom end, wherein the elongate leg extends from a saddle to a foot and has a handle disposed on the middle portion, wherein the saddle extends in an elongate shape between the first side direction and the second side direction, wherein the handle extends in an elongate shape between the first side direction and the second side direction, wherein the elongate leg middle portion is to the third side direction of an axis extending between the leg and the foot, wherein the elongate leg middle portion is to the first side direction of an axis extending between the top end of the elongate leg and the bottom end of the elongate leg; and wherein the handle is cantilevered and has a

Abstract: The disclosure includes a system and method for providing navigation guidance. The system includes a tracking application and a user. The tracking application determines a location of a user, determines a position of at least one object in proximity to the user, determines a path for the user to avoid the at least one object, generates linear and angular velocities that correspond to the path and generates directions that correspond to the linear and angular velocities. The user can receive the directions as audio instructions or via a tactile belt with motors that vibrate to convey the directions.

Abstract: Manual CPR apparatus allowing the application of force at two points separated by a line making a nonperpendicular angle relative to the longitudinal axis of the patient. The line separating the two force points may also lie out of the plane formed by the device's belt which circumnavigates the patient's torso. These geometrical configurations allow the facile application of the CPR force to the device by one or more operators located along the side of the patient. The device may have the capability to limit the achieved circular chest compression to one of a plurality of magnitudes. The device may also provide signals to indicate the appropriate times for applying pressure and may incorporate electrocardiogram and defibrillation components. The device may contact the patient's chest with a suction cup or other adhering component to assist in the patient's chest expanding in the interval between compressive strokes.

Abstract: A sauna apparatus for a half-body bath including a body having a concave structure surrounded with a bottom surface located horizontally on the ground and at least three surfaces connected to the bottom surface. The sauna apparatus also includes a first heating part and a seat disposed at the inside thereof. The sauna apparatus further includes a cover connected on top of the body that is movable-up and down to open and close the interior of the body. The sauna apparatus also includes a second heating part in the cover and shock absorbers to connect the body and the cover with each other. In addition, the sauna apparatus includes a seat driving part to move the seat in an advancing or opposite direction.

Abstract: A cartridge for holding surgical fasteners includes a base having a plurality of upstanding walls, adjacent pairs of walls defining spaces for holding surgical fasteners, at least one surgical fastener securing member movably connected to the base and movable relative to the base from an open position wherein fasteners can be loaded into the spaces, and a closed position wherein fasteners in the spaces are covered and held in the spaces, and a locking structure engageable between the base and the surgical fastener securing member for locking the surgical fastener securing member in the closed position.

Abstract: The present invention generally relates to compositions and methods for transdermal drug delivery. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction, treating wounds, or causing or promoting hair growth. For example, in one aspect, the present invention is generally directed to compositions for delivery of nitric oxide, transdermally and/or to a mucosal surface. The composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. In some embodiments, a composition comprising nitric oxide is unexpectedly stable and can be stored long-term.

Abstract: An apparatus for storing and dispensing a medication, including: a cartridge including a cavity for storing a first orally-administered or injectable medication for a patient; and a module, including a specially-programmed computer. The specially-programmed computer: attached to the cartridge, and arranged to: automatically generate or modify a medication regimen, including designation of a measure for the first orally-administered or injectable medication, for the patient by using information regarding a second medication, different from the first medication, prescribed for the patient, or real time physiological data for the patient; and transmit instructions to a medication device to extract the first orally-administered or injectable medication from the cartridge and non-intravenously dispense, into a container, an amount of the first orally-administered or injectable medication equal to the designated measure or the modified designated measure.

Abstract: A cap for a bottle includes a first portion, a second portion, and an end piece having a concave body and a hole. The second portion is configured to retain a first ingredient, and the bottle is configured to retain a second ingredient. The first portion may be threadingly secured to the second portion while the second portion plugs the bottle and the end piece is secured to the second portion. Unthreading of the first portion from the second portion causes the first ingredient to fall through the hole and mix with the second ingredient in the bottle.

Abstract: A multi flow multi venting nipple includes a teat having a flow aperture which allows for at least two different flow rates depending upon the operative radial orientation of the nipple. The nipple further includes a number of vent apertures, equal to the number of flow rates, formed by check valves extending through the nipple to reduce negative pressure during use. Each vent aperture is associated with a particular flow rate, and is radially oriented to be uppermost and vertically above the flow aperture during use at such flow rate. All vent apertures will be operable at once. The nipple further includes safety walls extending from the nipple and surrounding at least half the periphery of each check valve forming the vent apertures. The safety wall prevents unintentional and rough contact from damaging the check valves.

Abstract: A nipple abrasion protector consists of a generally disc-shaped translucent polymeric adhesive film with adhesively affixed to one side of a release paper. The protector is removed from the paper and applied to the nipple to prevent chafing from contact with a shirt or other garment during extended physical activities like running and is semi-transparent or translucent and not readily detectable during activities like swimming or surfing. In addition, the protector is perforated with pores for breathablilty and has a cross-hatched surface texture to improve adhesion and flexibility. Moreover, the removable nipple protector adheres tightly to the areola and is capable of resisting protrusion of the nipple. The protector is free from materials such as latex which may incite an allergic reaction.

Abstract: A feeding tube assembly for insertion and delivery of nutrients into an alimentary canal is disclosed. A method of facilitating the use of the feeding tube with an insufflation device is also disclosed. The feeding tube assembly has a feeding tube with opposite proximal and distal ends, a feeding passage extending between the proximal and distal ends, an outlet proximate the distal end and in fluid communication with the feeding passage, a port at the proximal end and in fluid communication with the outlet; and an air insufflation device fluidly connectable to the port comprising a compressible air bulb having a bulb inlet and a bulb outlet; an inlet check valve at the bulb inlet, an outlet check valve at the bulb outlet, and a relief valve fluidly connected to the bulb outlet.

Abstract: The feeding tube system includes an elongated shaft having a proximal portion, an opposing distal portion, and a central opening or lumen extending therethrough. The proximal portion is configured to remain outside a patient's body cavity and includes a first opening through which fluids can be introduced into the lumen. The distal portion is configured for disposing within a patient's body cavity and includes a second opening for discharging fluids from the lumen into the patient's body cavity. An interior retention balloon is provided at the distal portion of the elongated shaft. An external base positioned at the proximal portion of the feeding tube can include at least one exterior base balloon extending therefrom. The interior retention balloon and the at least one exterior base balloon are inflatable.

Abstract: The present application provides a glass composition comprising 10-50% by weight CaO, at least 15% and less than 50% by weight P2O5, less than 3% by weight Al2O3, less than 10% by weight Li2O, Na2O, and K2O combined, and 0-60% by weight of SrO, MgO, BaO, ZnO, or combinations thereof; dental compositions comprising the glass composition, and methods of making and using such dental compositions.

Abstract: The present disclosure relates to a method for coating a surface of a titanium implant with low crystalline hydroxyapatite having network- or island-like morphology and to an implant coated by such method.

Abstract: Disclosed are water-based cosmetic compositions comprising a synthetic non-associative thickening polymer, a synthetic associative thickening polymer, an emulsifier, a film forming polymer, and a liquid fatty substance. The ratio of the synthetic non-associative thickening polymer to the synthetic associative thickening polymer is greater than 1:1, or alternatively, said ratio is less than or equal to 1:1.

Abstract: The present invention relates to a cosmetic composition for making up and/or caring for the skin and/or the lips, comprising, in a physiologically acceptable medium, at least one oil, which is preferably non-volatile, at least hydrophobic silica aerogel particles, at least one hydrocarbon-based resin having a number-average molecular weight of less than or equal to 10 000 g/mol, the said composition comprising less than 5% by weight of water relative to the total weight of the composition, and preferably being anhydrous.

Abstract: The present invention relates to coated titanium dioxide particles, wherein at least one coating layer comprises an ester made from a mixture of fatty alcohol and C6 to C12 aliphatic acids as coating material.

Abstract: A composition is disclosed that includes pure silk fibroin-based protein fragments that are substantially devoid of sericin, wherein the composition has an average weight average molecular weight ranging from about 17 kDa to about 38 kDa, wherein the composition has a polydispersity of between about 1.5 and about 3.0, wherein the composition is substantially homogeneous, wherein the composition between 0 ppm to about 500 ppm of inorganic residuals, and wherein the composition includes between 0 ppm to about 500 ppm of organic residuals.

Abstract: A body cosmetic for application to wetted skin after bathing, and the like, which provide high moisturizing effects, spread well to all over the body, and are easy to apply. An oil-in-water body cosmetic for application to wetted skin, which contains a water-soluble polymer and the following components (A) to (C): (A) from 20 to 50% by mass of oily ingredients containing (A1) oil that is pasty at 25° C. and (A2) polar oil that is liquid at 25° C.

Abstract: Antiperspirant/deodorant compositions have lower, or even zero amounts of aluminum and/or zirconium antiperspirant actives. A polymer having one or more anhydride and/or diacid moieties, such as succinic (maleic) anhydride and/or diacid. The antiperspirant/deodorant compositions comprise a polymer with a non-zero acid value and a cationic species, which may be a cationic polymer, cationic molecule, cation, and/or a cationic carrier. Product are formed for the antiperspirant/deodorant composition, as well as a method of treating perspiration.

Abstract: Oral care compositions comprising: (a) a peroxide complex comprising a peroxide component and an N-vinyl heterocyclic polymer (e.g., poly-N-vinyl polylactam, or poly-N-vinyl-polyimide); (b) a whitening agent (e.g., hydrogen peroxide); and (c) an orally acceptable carrier. In one embodiment, the carrier comprises a film forming material. Methods are also provided for making an oral care composition comprising: (a) mixing a whitening agent, silicone adhesive and carrier fluid to form a homogenous mixture; (b) adding a peroxide complex to said homogenous mixture, wherein said complex comprises hydrogen peroxide and an N-vinyl heterocyclic polymer; and (c) mixing under vacuum.

Abstract: The invention relates to particles including, relative in each case to the particle weight, 30 to 90 wt. % of polyalphaolefin wax(es) and 10 to 70 wt. % of one or more cosmetic active agents, selected from fragrances, cooling active agents and mixtures of fragrances and cooling active agents, as well as to cosmetic compositions containing water and 0.01 to 10 wt. %, relative to the weight of the cosmetic composition, of one or more of the aforementioned particles.

Abstract: A lip balm product having a synthetic ceramide, an anti-irritant compound, sodium hyaluronate, cosmetic wax, boswellic acids and/or esters and/or salts thereof, extract of the Portuluca pilosa plant, matrikin-mimetic peptide, dehydrated microspheres of marine collagen and glycosaminoglycans, and mica along with optional lip balm formulation acceptable carriers and/or solvents. Where desired, the lip balm may further contain medicinal agents suitable for the treatment of various conditions of the lip.

Abstract: The present invention discloses a preparation method for toothpaste composition containing ganoderma lucidum component, wherein the ganoderma lucidum component is sporoderm-broken ganoderma lucidum spore, it comprises the following steps: (1) dissolve water, sorbitol, PEG-8, propylene glycol, sodium saccharine, sodium benzoate and the extract of opuntia in a toothpaste-making pot; (2) premix calcium hydrogen phosphate, hydrated silica, sodium lauryl sulfate, cellulose gum, hydroxyethyl cellulose, sporoderm-broken ganoderma lucidum spore, Panax notoginseng powder, and radix scutellariae root powder in powder tank evenly to form a mixture; (3) stir the mixture obtained in step (2) under vacuum and inhale into the toothpaste-making pot of step (1); control the vacuum degree at minus 0.098 to minus 0.1 Mpa and stir for 15 minutes; (4) inhale the essence into the toothpaste-making pot, stir for 10 minutes, and discharge.

Abstract: Provided are methods of treating pain, including neuropathic pain, in human and veterinary individuals. These methods employ locally administrable pharmaceutical gallium compositions, including pharmaceutical gallium compositions suitable for administration to the skin and mucous membranes. The compositions comprise pharmaceutically acceptable gallium compounds, such as gallium maltolate or gallium nitrate, together with pharmaceutically acceptable carriers suitable for local administration, including those suitable for topical administration. The administration of such compositions provides relief from pain, itching, allodynia, hyperalgesia, and related symptoms.

Abstract: A method of treating chronic post-myocardial infarction including helical needle transendocardial delivery of autologous bone marrow (ABM) mononuclear cells around regions of hypo or akinesia in chronic post-myocardial infarction (MI) patients. The treatment is safe and improves ejection fraction (EF).

Abstract: Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include administering at least one pharmaceutical agent onto a SEM graft in the skull base of the subject. Also provided are methods of treating a neurological disorder or pain in a subject that include forming a SEM graft in the skull base of the subject and administering at least one pharmaceutical agent onto the SEM graft in the skull base of the subject. Also provided are methods of forming a SEM graft in the skull base of a subject, compositions for administration onto a SEM graft in the skull base or into an endonasal reservoir or endonasal reservoir device in a subject, and devices for administering such compositions onto a SEM graft in the skull base of a subject.

Abstract: Novel classes of multi-arm polyalkylene oxide-based materials including PEG nanocarriers, nanogel particles, and aggregated nanogel particles are disclosed. These classes of compositions may be associated with therapeutic agents and targeting moieties, or visibility enhancing agents, and may have a modified surface structure. In some embodiments the PEG-based materials can be made to provide relatively high drug loads with improved solubility and targeted delivery.

Abstract: The present invention is directed to phospholipid compositions and methods of preparation of phospholipid depots that are injectable through a fine needle. The phospholipid depots prepared by the methods described herein comprise nanometer-sized phospholipid particles and exhibit a higher degree of structural order compared to compositions prepared by other methods.

Abstract: The present invention provides biodegradable polymer particle delivery compositions based on polymers, such as polyester amide (PEA) and polyester urethane (PEUR) polymers, that contain amino acids in the polymer. The polymer particle delivery compositions can be formulated as a liquid dispersion of polymer particles with the bioactive agents dispersed in the particle or conjugated attached to polymer molecules or particle surfaces. The bioactive agents can include drugs, polypeptides, DNA and cells for cell-based therapies using particles sized for local, mucosal or circulatory delivery. Methods of treating a disease by administering to a subject the polymer particle delivery composition, which incorporates a bioactive agent suitable for treatment of the disease, or its symptoms, are also included.

Abstract: The present invention relates to a powder formulation which reduces side effect risk of a medicine having a side effect of drug-induced photodermatosis and increases therapeutic effect, and relates to the method for producing the same. Said powder formulation makes inhalation therapy possible by carrying out aerosolization easily, and since pharmacological effect in lung local part is increased, it is possible to decrease the dose. Skin transmigration of said medicine is controlled by a lung specific delivery technology, and photodermatosis which is a side effect can be controlled.

Abstract: Influenza vaccines are administered using solid biodegradable microneedles. The microneedles are fabricated from the influenza vaccine in combination with solid excipient(s) and, after penetrating the skin, they dissolve in situ and release the vaccine to the immune system. The influenza vaccine is (i) a purified influenza virus surface antigen vaccine, rather than a live vaccine or a whole-virus or split inactivated vaccine (ii) an influenza vaccine prepared from viruses grown in cell culture, not eggs, (iii) a monovalent influenza vaccine e.g. for immunizing against a pandemic strain, (iv) a bivalent vaccine, (v) a tetravalent or >4-valent vaccine, (vi) a mercury-free vaccine, or (vii) a gelatin-free vaccine.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: Abuse-deterrent dosage forms (e.g., orally administered dosage forms, transdermal dosage forms, suppositories, etc.), processes for formulating pharmaceutical dosage forms comprising an active agent susceptible to abuse (e.g., an opioid agonist, a benzodiazepine, a stimulant) such that the resulting dosage forms are abuse-deterrent are described. Also described are methods of deterring abuse of pharmaceutical dosage forms.

Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising fumarate esters are described.

Abstract: A method for producing a microcapsule powder includes a concentration step. In the concentration step, an aqueous dispersion of a microcapsule is supplied into a cyclone, and the aqueous dispersion is then concentrated. The concentration step includes an aqueous dispersion-supplying step and a concentrated dispersion-recovering step. In the aqueous dispersion-supplying step, the aqueous dispersion is supplied into a cylindrical member inlet. In the concentrated dispersion-recovering step, a microcapsule dispersion is recovered. The microcapsule dispersion is discharged through a conical member outlet.

Abstract: A patch for external use which has a laminate structure comprising a substrate and a pressure-sensitive adhesive layer which contains a styrene/isoprene/styrene block copolymer as the base and further contains a tackifier resin consisting of a rosin resin and at least one other tackifier resin, a softening agent consisting of polybutene and liquid paraffin, a fatty acid ester, and fentanyl, characterized in that the weight ratio of the rosin resin to fentanyl is 1 to 5, the weight ratio of the rosin resin to the whole tackifier resin is 0.1 to 0.6, and the tackifier resin accounts for 30 to 60wt % of the whole pressure-sensitive adhesive layer. The patch is excellent in the permeation of fentanyl through the skin and in storage stability, and is weak in irritation to skin.

Abstract: A medicated pad which may be removably placed over a skin disorder such as acne to provide a relatively rapid treatment for relieving such skin disorder and may then be easily removed from the person.

Abstract: A kit for treating insect bites includes a plurality of patches of different size and shape, and a container of a composition containing extracts of garlic and parsley. The patches have a pad bordered by a margin coated with a pressure sensitive adhesive. The extracts of parsley include apiol and myristicin, and the extracts of garlic include allicin. In use, the composition is deposited onto the pad and the patch is placed over an affected area and adhered to the skin with the pressure sensitive adhesive.

Abstract: The invention is in particular concerned with a food product comprising one or more fats or oils and a carotenoid compound. The products of the invention may be used in reducing elevated total cholesterol, triglycerides and inflammatory damage, as well as improving tissue microcirculation and tissue oxygenation.

Abstract: This invention is related to dermal matrices and production method thereof, having within its structure micro particles having antioxidant agents with synergistic effects, providing speedy repair of the dermal tissue, used in chronic wound treatments, basically comprising the steps of preparing the dermal matrix system (11), forming micro particles (12), combining the micro particles with the dermal matrix system.

Abstract: A pharmaceutical composition is described that is suitable for delivery from a pressurized container. The composition is free of polar excipients and comprises: (a) a propellant component that consists essentially of 1,1-difluoroethane (R-152a); (b) a surfactant component that comprises oleic acid; and (c) a drug component that consists of salbutamol sulphate. The pharmaceutical composition can be delivered using a metered dose inhaler (MDI).

Abstract: The present invention provides a pharmaceutical that can be used widely for intractable neurological diseases, inflammatory diseases, etc. The immune cell activation inhibitor of the present invention contains bromovalerylurea or a derivative thereof. The immune cell activation inhibitor of the present invention can be used as a pharmaceutical for, for example: chronic neurological diseases such as Parkinson's disease and Alzheimer's disease; acute neurological diseases such as cerebral infarction and brain injury; and inflammatory diseases such as systemic inflammatory response syndromes.

Abstract: In various embodiments, methods and compositions for treating Raynaud's disease and Raynaud's phenomenon are provided. Topical administration of a semisolid composition comprising a prostaglandin E1 compound provides the desired relief of the Raynaud's disease or Raynaud's phenomenon without the possible complications of systemic administration. The semisolid composition can be administered as needed, or in a regimen of several doses per day.

Abstract: Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.

Abstract: Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.

Abstract: [Problem to be solved] Provision of an agent for preventing or treating a functional brain disease and/or inhibiting symptom development of the same. [Means for solving the problems] An agent for preventing or treating a functional brain disease and/or inhibiting symptom development of the same, which comprises (2R)-2-propyloctanoic acid or a salt thereof. The agent for preventing or treating a functional brain disease and/or inhibiting symptom development of the same, which comprises (2R)-2-propyloctanoic acid or a salt thereof, can be safely administered to patients of, for example, functional brain diseases such as depression, menopausal mood disorder, perimenopausal mood disorder, panic disorder, irritable bowel syndrome, social anxiety disorder, post-traumatic stress disorder or the like, and also can show excellent effects.

Abstract: The present invention relates to the treatment of Senile Dementia of the Alzheimer's Type (SDAT) by administering to the patient and effective amount of a compound selected from the group consisting of: 1-alkyl, 2-acyl-glyceraldehyde-3-phosphate (G3P); 1-alkyl, 2-acyl-glycerol; and 1-alkyl, 2-acyl-glycerylphosphatidylethanolamine (CGPE) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention is based on the discovery that motor neurons derived from patients with a neurodegenerative disease have decreased delayed rectifier potassium current and increased persistent sodium current compared to motor neurons derived from control healthy individuals. The present invention is also based on the discovery that the class of compounds known as “potassium channel openers” can be used to treat neurodegenerative diseases, including ALS, Parkinson's disease, Alzheimer's disease, epilepsy, and pain.